DIA 2013 49th Annual Meeting
Click here to go to the previous page
Expediting Drug Development and Review for Serious Conditions
Track
:
Track 08:Regulatory Affairs and Submissions
Program Code:
211
Date:
Tuesday, June 25, 2013
Time:
8:00 AM to 9:30 AM
EST
Location:
253A
CHAIR
:
Robert J. Temple, MD (SCHAGY), Deputy Center Director for Clinical Science, CDER, FDA, United States
SPEAKER
(S):
Hans-Georg Eichler, MD,MSc (SPKAGY), Senior Medical Officer, European Medicines Agency, European Union, United Kingdom Robert Metcalf, PhD (SPKNON), Vice President, Global Regulatory Affairs - US, Eli Lilly and Company, United States
Description
This forum will provide clarity about FDA's expedited drug development and review programs and ways in which the EMA enables drug development. It will emphasize the importance of expediting drug development to address the critical need for new therapies to treat serious or life-threatening diseases that lack therapeutic alternatives.
This session is a part of:
This session is a part of: